Hemogenyx Advances HG-CT-1 CAR-T Program With Manufacturing Transfer and Trial Expansion

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has issued an announcement.

Hemogenyx Pharmaceuticals has completed the technology transfer of manufacturing for its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia to contract developer and manufacturer Made Scientific. A comparability data package submitted to the U.S. Food and Drug Administration shows that HG-CT-1 made externally is comparable to the in-house product, strengthening the robustness and scalability of the therapy’s production.

The company will now begin recruiting adult patients for treatment at a higher dose level in its ongoing Phase 1 trial, while also initiating enrollment of pediatric patients at the lowest dose, marking a key expansion of the program. Management says these steps position Hemogenyx to accelerate development of HG-CT-1 for patients with limited treatment options, while its CDX and CBR candidates continue to progress alongside the lead CAR-T program.

The most recent analyst rating on (GB:HEMO) stock is a Hold with a £725.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Spark’s Take on HEMO Stock

According to Spark, TipRanks’ AI Analyst, HEMO is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

To see Spark’s full report on HEMO stock, click here.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals plc is a clinical-stage biopharmaceutical group focused on developing innovative therapies for blood and autoimmune diseases. Listed on the London Stock Exchange and headquartered in London with U.S. operations in New York, the company is advancing multiple product candidates and platform technologies aimed at underserved hematology markets.

Average Trading Volume: 28,584

Technical Sentiment Signal: Buy

Current Market Cap: £61.04M

Learn more about HEMO stock on TipRanks’ Stock Analysis page.